Edition:
India

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

42.61GBp
15 Jul 2019
Change (% chg)

-- (--)
Prev Close
42.61
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
6,628,107
52-wk High
391.40
52-wk Low
20.98

Select another date:

Sat, Jul 13 2019

Indivior loses appeal to block generic Suboxone opioid treatments

A divided federal appeals court on Friday ruled against Indivior Plc in its bid to stop Dr. Reddy's Laboratories Ltd and Alvogen from selling generic versions of its opioid addiction treatment Suboxone film that infringed its patents.

Indivior loses appeal to block generic Suboxone opioid treatments

A divided federal appeals court on Friday ruled against Indivior Plc in its bid to stop Dr. Reddy's Laboratories Ltd and Alvogen from selling generic versions of its opioid addiction treatment Suboxone film that infringed its patents.

UPDATE 1-Indivior loses appeal to block generic Suboxone opioid treatments

July 12 A divided federal appeals court on Friday ruled against Indivior Plc in its bid to stop Dr. Reddy's Laboratories Ltd and Alvogen from selling generic versions of its opioid addiction treatment Suboxone film that infringed its patents.

Indivior loses appeal to block generic Suboxone opioid treatments

July 12 A divided federal appeals court on Friday ruled against Indivior Plc in its bid to stop Dr. Reddy's Laboratories Ltd and Alvogen from selling generic versions of its opioid addiction treatment Suboxone film that infringed its patents.

Indivior lifts FY profit view on slower erosion of Suboxone market share

Drugmaker Indivior Plc on Thursday raised its profit and revenue guidance for the full year as its blockbuster opioid drug Suboxone lost market share at a lower pace than expected, bolstering its first-half performance.

Indivior signs deal to sell schizophrenia drug in Canada

British drugmaker Indivior Plc on Thursday signed a licensing agreement with HLS Therapeutics Inc for the sale of its schizophrenia drug Perseris in Canada.

Indivior signs deal to sell schizophrenia drug in Canada

British drugmaker Indivior Plc on Thursday signed a licensing agreement with HLS Therapeutics Inc for the sale of its schizophrenia drug Perseris in Canada.

Indivior signs deal to sell schizophrenia drug in Canada

May 9 British drugmaker Indivior Plc on Thursday signed a licensing agreement with HLS Therapeutics Inc for the sale of its schizophrenia drug Perseris in Canada.

UPDATE 3-Indivior's Suboxone decline slower than feared as company bets on new opioid drug

* Stock closes up 5.2 percent (Adds graphics, CFO comment, details on DoJ investigation)

Indivior shares plummet, Reckitt hurt on U.S. charges over opioid prescriptions

(This April 10 story refiles to fix scrambled syntax in paragraph five)

Select another date: